Table 1.
The L/BW ratio and serum parameters as adverse effects of RXR agonists
| PBS/vehicle | PPE/vehicle | PPE/NEt-4IB 0.015% |
PPE/Bexarotene 0.015% |
|
|---|---|---|---|---|
| L/BW ratio | 0.050 ± 0.002 | 0.049 ± 0.001 | 0.053 ± 0.001# | 0.073 ± 0.002*, #, ## |
| TG (mg/dl) | 173 ± 12 | 140 ± 11* | 177 ± 11# | 255 ± 17*, #, ## |
| Glucose (mg/dl) | 482 ± 23 | 479 ± 21 | 565 ± 35 | 492 ± 30 |
| AST (IU/L) | 125 ± 13 | 151 ± 12 | 153 ± 19 | 123 ± 12 |
| ALT (IU/L) | 56 ± 9 | 66 ± 7 | 54 ± 5 | 31 ± 4*, #, ## |
| ALP (IU/L) | 275 ± 10 | 303 ± 9 | 296 ± 6 | 406 ± 11*, #, ## |
| LAP (IU/L) | 54 ± 2 | 51 ± 1 | 53 ± 1 | 52 ± 1 |
| AMY (IU/L) | 5352 ± 509 | 4608 ± 276 | 5155 ± 445 | 6049 ± 204# |
*Significant differences (P < 0.05) between PBS/vehicle and PPE/vehicle or PPE/Bexarotene 0.015%. #Significant differences (P < 0.05) between PPE/vehicle and PPE/NEt-4IB 0.015% or PPE/bexarotene 0.015%. ##Significant differences (P < 0.05) between PPE/NEt-4IB 0.015% and PPE/bexarotene 0.015%